Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis
Background Resection of hepatocellular carcinoma (HCC) is potentially curative; however, recurrence is common. To date, few or no effective adjuvant therapies have been adequately investigated. This study evaluates the efficacy of adjuvant iodine-131-lipiodol after hepatic resection through the expe...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2011-04, Vol.16 (2), p.125-132 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 132 |
|---|---|
| container_issue | 2 |
| container_start_page | 125 |
| container_title | International journal of clinical oncology |
| container_volume | 16 |
| creator | Chua, Terence C. Saxena, Akshat Chu, Francis Butler, S. Patrick Quinn, Richard J. Glenn, Derek Morris, David L. |
| description | Background
Resection of hepatocellular carcinoma (HCC) is potentially curative; however, recurrence is common. To date, few or no effective adjuvant therapies have been adequately investigated. This study evaluates the efficacy of adjuvant iodine-131-lipiodol after hepatic resection through the experience of a single-center hepatobiliary service of managing this disease.
Patients and methods
All patients who underwent hepatic resection for HCC and received adjuvant iodine-131-lipiodol between January 1991 and August 2009 were selected for inclusion into the experimental group. A group composed of patients treated during the same time period without adjuvant iodine-131-lipiodol was identified through the unit’s HCC surgery database for comparison. The endpoints of this study were disease-free survival and overall survival.
Results
Forty-one patients who received adjuvant iodine-131-lipiodol after hepatic resection were compared with a matched group of 41 patients who underwent hepatic resection only. The median disease-free and overall survival were 24 versus 10 months (
P
= 0.032) and 104 versus 19 months (
P
= 0.001) in the experimental and control groups, respectively. Rates of intrahepatic-only recurrences (73 vs. 37%;
P
= 0.02) and surgical and nonsurgical treatments for recurrences (84 vs. 56%;
P
= 0.04) were higher in the experimental group compared to the control group.
Conclusion
The finding of this study corroborates the current evidence from randomized and nonrandomized trials that adjuvant iodine-131-lipiodol improves disease-free and overall survival in patients with HCC after hepatic resection. The lengthened disease-free survival after adjuvant iodine-131-lipiodol allows for further disease-modifying treatments to improve the overall survival. |
| doi_str_mv | 10.1007/s10147-010-0143-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_860452971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2312922041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-80d5c3e0977535753ac451ddd36e9e2db349c1a4bfb5a2991fef2fd7c6eba2653</originalsourceid><addsrcrecordid>eNp1kMtOBCEQRYnR-Bj9ADeGuEcpaBpxZ4yvxMSNrgkNtMOkp2mhWzN_L-P4WLmo3CJ16xY5CB0DPQNK5XkGCpUkFGipihO1hfaLSiKlZNul5xUQVTOxhw5yXlAKshZsF-0xoDVARfdRvveDGYPFyWdvxxB7_BHGOY7pS-M0YuMW07vpRxyiC70nwIF0YSiv2OG2GOfriGh9102dSdiaZEMfl-YSG2zjcjCpXHj32PSmW-WQD9FOa7rsj751hl5ub56v78nj093D9dUjsVzBSC6oE5Z7qqQUXJQythLgnOO1V565hlfKgqmathGGKQWtb1nrpK19Y1gt-AydbnKHFN8mn0e9iFMqn8j6oqaVYEpCMcHGZFPMOflWDyksTVppoHpNWW8o60JZrylrVXZOvoOnZund78YP1mJgG0Muo_7Vp7_L_6d-AkyhiWE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>860452971</pqid></control><display><type>article</type><title>Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Chua, Terence C. ; Saxena, Akshat ; Chu, Francis ; Butler, S. Patrick ; Quinn, Richard J. ; Glenn, Derek ; Morris, David L.</creator><creatorcontrib>Chua, Terence C. ; Saxena, Akshat ; Chu, Francis ; Butler, S. Patrick ; Quinn, Richard J. ; Glenn, Derek ; Morris, David L.</creatorcontrib><description>Background
Resection of hepatocellular carcinoma (HCC) is potentially curative; however, recurrence is common. To date, few or no effective adjuvant therapies have been adequately investigated. This study evaluates the efficacy of adjuvant iodine-131-lipiodol after hepatic resection through the experience of a single-center hepatobiliary service of managing this disease.
Patients and methods
All patients who underwent hepatic resection for HCC and received adjuvant iodine-131-lipiodol between January 1991 and August 2009 were selected for inclusion into the experimental group. A group composed of patients treated during the same time period without adjuvant iodine-131-lipiodol was identified through the unit’s HCC surgery database for comparison. The endpoints of this study were disease-free survival and overall survival.
Results
Forty-one patients who received adjuvant iodine-131-lipiodol after hepatic resection were compared with a matched group of 41 patients who underwent hepatic resection only. The median disease-free and overall survival were 24 versus 10 months (
P
= 0.032) and 104 versus 19 months (
P
= 0.001) in the experimental and control groups, respectively. Rates of intrahepatic-only recurrences (73 vs. 37%;
P
= 0.02) and surgical and nonsurgical treatments for recurrences (84 vs. 56%;
P
= 0.04) were higher in the experimental group compared to the control group.
Conclusion
The finding of this study corroborates the current evidence from randomized and nonrandomized trials that adjuvant iodine-131-lipiodol improves disease-free and overall survival in patients with HCC after hepatic resection. The lengthened disease-free survival after adjuvant iodine-131-lipiodol allows for further disease-modifying treatments to improve the overall survival.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-010-0143-9</identifier><identifier>PMID: 21061140</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Antineoplastic Agents - therapeutic use ; Cancer Research ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - radiotherapy ; Carcinoma, Hepatocellular - surgery ; Carcinoma, Hepatocellular - therapy ; Case-Control Studies ; Cohort Studies ; Disease-Free Survival ; Ethiodized Oil - therapeutic use ; Female ; Humans ; Iodine Radioisotopes - therapeutic use ; Liver cancer ; Liver Neoplasms - drug therapy ; Liver Neoplasms - radiotherapy ; Liver Neoplasms - surgery ; Liver Neoplasms - therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local - diagnosis ; Nuclear medicine ; Oncology ; Original Article ; Prognosis ; Radiopharmaceuticals - therapeutic use ; Radiotherapy, Adjuvant ; Randomized Controlled Trials as Topic ; Surgery ; Surgical Oncology ; Treatment Outcome</subject><ispartof>International journal of clinical oncology, 2011-04, Vol.16 (2), p.125-132</ispartof><rights>Japan Society of Clinical Oncology 2010</rights><rights>Japan Society of Clinical Oncology 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-80d5c3e0977535753ac451ddd36e9e2db349c1a4bfb5a2991fef2fd7c6eba2653</citedby><cites>FETCH-LOGICAL-c391t-80d5c3e0977535753ac451ddd36e9e2db349c1a4bfb5a2991fef2fd7c6eba2653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-010-0143-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-010-0143-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21061140$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chua, Terence C.</creatorcontrib><creatorcontrib>Saxena, Akshat</creatorcontrib><creatorcontrib>Chu, Francis</creatorcontrib><creatorcontrib>Butler, S. Patrick</creatorcontrib><creatorcontrib>Quinn, Richard J.</creatorcontrib><creatorcontrib>Glenn, Derek</creatorcontrib><creatorcontrib>Morris, David L.</creatorcontrib><title>Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
Resection of hepatocellular carcinoma (HCC) is potentially curative; however, recurrence is common. To date, few or no effective adjuvant therapies have been adequately investigated. This study evaluates the efficacy of adjuvant iodine-131-lipiodol after hepatic resection through the experience of a single-center hepatobiliary service of managing this disease.
Patients and methods
All patients who underwent hepatic resection for HCC and received adjuvant iodine-131-lipiodol between January 1991 and August 2009 were selected for inclusion into the experimental group. A group composed of patients treated during the same time period without adjuvant iodine-131-lipiodol was identified through the unit’s HCC surgery database for comparison. The endpoints of this study were disease-free survival and overall survival.
Results
Forty-one patients who received adjuvant iodine-131-lipiodol after hepatic resection were compared with a matched group of 41 patients who underwent hepatic resection only. The median disease-free and overall survival were 24 versus 10 months (
P
= 0.032) and 104 versus 19 months (
P
= 0.001) in the experimental and control groups, respectively. Rates of intrahepatic-only recurrences (73 vs. 37%;
P
= 0.02) and surgical and nonsurgical treatments for recurrences (84 vs. 56%;
P
= 0.04) were higher in the experimental group compared to the control group.
Conclusion
The finding of this study corroborates the current evidence from randomized and nonrandomized trials that adjuvant iodine-131-lipiodol improves disease-free and overall survival in patients with HCC after hepatic resection. The lengthened disease-free survival after adjuvant iodine-131-lipiodol allows for further disease-modifying treatments to improve the overall survival.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer Research</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - radiotherapy</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Case-Control Studies</subject><subject>Cohort Studies</subject><subject>Disease-Free Survival</subject><subject>Ethiodized Oil - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - radiotherapy</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Nuclear medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Radiotherapy, Adjuvant</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Treatment Outcome</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kMtOBCEQRYnR-Bj9ADeGuEcpaBpxZ4yvxMSNrgkNtMOkp2mhWzN_L-P4WLmo3CJ16xY5CB0DPQNK5XkGCpUkFGipihO1hfaLSiKlZNul5xUQVTOxhw5yXlAKshZsF-0xoDVARfdRvveDGYPFyWdvxxB7_BHGOY7pS-M0YuMW07vpRxyiC70nwIF0YSiv2OG2GOfriGh9102dSdiaZEMfl-YSG2zjcjCpXHj32PSmW-WQD9FOa7rsj751hl5ub56v78nj093D9dUjsVzBSC6oE5Z7qqQUXJQythLgnOO1V565hlfKgqmathGGKQWtb1nrpK19Y1gt-AydbnKHFN8mn0e9iFMqn8j6oqaVYEpCMcHGZFPMOflWDyksTVppoHpNWW8o60JZrylrVXZOvoOnZund78YP1mJgG0Muo_7Vp7_L_6d-AkyhiWE</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Chua, Terence C.</creator><creator>Saxena, Akshat</creator><creator>Chu, Francis</creator><creator>Butler, S. Patrick</creator><creator>Quinn, Richard J.</creator><creator>Glenn, Derek</creator><creator>Morris, David L.</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20110401</creationdate><title>Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis</title><author>Chua, Terence C. ; Saxena, Akshat ; Chu, Francis ; Butler, S. Patrick ; Quinn, Richard J. ; Glenn, Derek ; Morris, David L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-80d5c3e0977535753ac451ddd36e9e2db349c1a4bfb5a2991fef2fd7c6eba2653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer Research</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - radiotherapy</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Case-Control Studies</topic><topic>Cohort Studies</topic><topic>Disease-Free Survival</topic><topic>Ethiodized Oil - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - radiotherapy</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Nuclear medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Radiotherapy, Adjuvant</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chua, Terence C.</creatorcontrib><creatorcontrib>Saxena, Akshat</creatorcontrib><creatorcontrib>Chu, Francis</creatorcontrib><creatorcontrib>Butler, S. Patrick</creatorcontrib><creatorcontrib>Quinn, Richard J.</creatorcontrib><creatorcontrib>Glenn, Derek</creatorcontrib><creatorcontrib>Morris, David L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chua, Terence C.</au><au>Saxena, Akshat</au><au>Chu, Francis</au><au>Butler, S. Patrick</au><au>Quinn, Richard J.</au><au>Glenn, Derek</au><au>Morris, David L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>16</volume><issue>2</issue><spage>125</spage><epage>132</epage><pages>125-132</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
Resection of hepatocellular carcinoma (HCC) is potentially curative; however, recurrence is common. To date, few or no effective adjuvant therapies have been adequately investigated. This study evaluates the efficacy of adjuvant iodine-131-lipiodol after hepatic resection through the experience of a single-center hepatobiliary service of managing this disease.
Patients and methods
All patients who underwent hepatic resection for HCC and received adjuvant iodine-131-lipiodol between January 1991 and August 2009 were selected for inclusion into the experimental group. A group composed of patients treated during the same time period without adjuvant iodine-131-lipiodol was identified through the unit’s HCC surgery database for comparison. The endpoints of this study were disease-free survival and overall survival.
Results
Forty-one patients who received adjuvant iodine-131-lipiodol after hepatic resection were compared with a matched group of 41 patients who underwent hepatic resection only. The median disease-free and overall survival were 24 versus 10 months (
P
= 0.032) and 104 versus 19 months (
P
= 0.001) in the experimental and control groups, respectively. Rates of intrahepatic-only recurrences (73 vs. 37%;
P
= 0.02) and surgical and nonsurgical treatments for recurrences (84 vs. 56%;
P
= 0.04) were higher in the experimental group compared to the control group.
Conclusion
The finding of this study corroborates the current evidence from randomized and nonrandomized trials that adjuvant iodine-131-lipiodol improves disease-free and overall survival in patients with HCC after hepatic resection. The lengthened disease-free survival after adjuvant iodine-131-lipiodol allows for further disease-modifying treatments to improve the overall survival.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>21061140</pmid><doi>10.1007/s10147-010-0143-9</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2011-04, Vol.16 (2), p.125-132 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_journals_860452971 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Agents - therapeutic use Cancer Research Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - radiotherapy Carcinoma, Hepatocellular - surgery Carcinoma, Hepatocellular - therapy Case-Control Studies Cohort Studies Disease-Free Survival Ethiodized Oil - therapeutic use Female Humans Iodine Radioisotopes - therapeutic use Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - radiotherapy Liver Neoplasms - surgery Liver Neoplasms - therapy Male Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - diagnosis Nuclear medicine Oncology Original Article Prognosis Radiopharmaceuticals - therapeutic use Radiotherapy, Adjuvant Randomized Controlled Trials as Topic Surgery Surgical Oncology Treatment Outcome |
| title | Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A35%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatic%20resection%20with%20or%20without%20adjuvant%20iodine-131-lipiodol%20for%20hepatocellular%20carcinoma:%20a%20comparative%20analysis&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Chua,%20Terence%20C.&rft.date=2011-04-01&rft.volume=16&rft.issue=2&rft.spage=125&rft.epage=132&rft.pages=125-132&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-010-0143-9&rft_dat=%3Cproquest_cross%3E2312922041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=860452971&rft_id=info:pmid/21061140&rfr_iscdi=true |